380,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 380,000 shares of the biotechnology company's stock, valued at approximately $581,000. Quinn Opportunity Partners LLC owned approximately 0.25% of Heron Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Congress Park Capital LLC lifted its stake in Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after acquiring an additional 477,417 shares in the last quarter. JPMorgan Chase & Co. increased its position in Heron Therapeutics by 172.2% during the 4th quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock worth $861,000 after buying an additional 356,053 shares during the period. XTX Topco Ltd grew its holdings in shares of Heron Therapeutics by 449.0% during the 3rd quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company's stock worth $592,000 after purchasing an additional 243,363 shares in the last quarter. CM Management LLC boosted its holdings in shares of Heron Therapeutics by 40.0% in the 4th quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock valued at $1,071,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Heron Therapeutics in the 4th quarter valued at $208,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX traded down $0.01 during trading on Tuesday, hitting $1.92. The company had a trading volume of 696,140 shares, compared to its average volume of 2,363,304. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The firm has a market capitalization of $292.47 million, a P/E ratio of -10.67 and a beta of 1.39. The stock has a 50 day simple moving average of $2.07 and a 200 day simple moving average of $1.78.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. As a group, analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Friday. StockNews.com cut Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.